Disorders of platelet function

Critical Reviews in Oncology/Hematology

Volumn 22, Issue 1, 1996, Pages 1-25

  Fuse, Ichiro ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING; HUMAN; REVIEW; THROMBOCYTE DISORDER; THROMBOCYTE DYSFUNCTION;

EID: 0030051631     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(94)00167-7     Document Type: Review

References (375)

1. Turitto VT, Baumgartner HR. Physical factors influencing platform deposition on subendothelium: importance of blood shear rate. Ann NY Acad Sci 283:284-292, 1977.
2. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med 92:750-764, 1978.
3. Pareti FI, Fujimur Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 261:15310-15315, 1986.
4. Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry 25:8357-8361, 1986.
5. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 65:85-90, 1985.
6. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 74:182-192, 1989.
7. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffman T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 83:288-297, 1988.
8. Pytela R, Pierschbacher MD, Ruoslahti E. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 82:5766-5700, 1985.
9. Lam SCT, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 264:3742-3749, 1989.
10. Hemler ME, Couse C, Takada Y, Sonnenberg A. Multiple very late antigen (VLA) heterodimers on platelets: evidence for distinct VLA-2, VLA-5 (fibronectin receptor) and VLA-6 structure. J Biol Chem 263:7660-7665, 1988.
11. Pioyrowicz RS, Orchekowski RP, Nugent DJ, Yamada KY, Kunicki TJ. Glycoprotein Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. J Cell Biol 106:1359-1364, 1988.
12. Giancotti FG, Languino LR, Zanetti A, Peri G, Tarone G, Dejana E. Platelets express a membrane protein complex immunologically related to the fibroblast fibronectin receptor and distinct from GPIIb/IIIa. Blood 69:1535-1538, 1987.
13. Kunicki TJ, Nugent DJ, Staats SJ, Orchekowski RP, Wayner EA, Carter WG. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem 263:4516-4519, 1988.
14. Santoro SA. Identification of a 160000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 46:913-920, 1986.
15. Nieuwenhuis HK, Sakariassen KS, Houdijk WPM, Nievelstein PFEM, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium. A defect in platelet spreading. Blood 68:692-695, 1986.
16. Tandon NN, Kralisz U, Jamieson GJ. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 264:7576-7583, 1989.
17. Asch AS, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondin membrane receptor. J Clin Invest 79:1054-1061, 1987.
18. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature 336:487-489, 1988.
19. Hynes RO. Integrins: a family of cell surface receptors. Cell 48:549-554, 1987.
20. Arnaout MA. Structure and function of the leucocyte adhesion molecules CD11/CD18. Blood 75:1037-1050, 1990.
21. Bernard J, Soulier JP. Sur une nouvelle variete de dystrophie thrombocytaire hemorragipare congenitale. Semin Hop Paris 24:3217-3223, 1948.
22. George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 311:1084-1098, 1984.
23. Nurden AT. Platelet membrane glycoproteins and their clinical aspects. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J, eds. Thrombosis and Haemostasis. Leuven, Belgium: Univeristy Press, 1987; 93-104.
24. George JN, Nurden AT. Inherited disorders of the platelet membrane: Glanzmann's thrombasthenia and Bernard-Soulier syndrome. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice, Second Edition. Philadelphia: Lippincott, 1987; 726-740.
25. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 255:720-722, 1975.
26. Jenkins CSP, Phillips DR, Clemetson KJ, Meyer D, Larrieau M-J, Luscher EF. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest 57:112-124, 1976.
27. Clemetson KJ, McGregor JL, James E, Dechavanne M, Luscher EF. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 70:304-311, 1982.
28. Berndt MC, Gregory C, Chong BH, Zola H, Castaldi PA. Additional glycoprotein defects in Bernard-Soulier's syndrome: confirmation of genetic basis by parental analysis. Blood 62:800-807, 1983.
29. 2-glycoprotein. Proc Natl Acad Sci USA 84:5615-5619, 1987.
30. Titani K, Takio K, Handa M, Ruggeri ZM. Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci USA 84:5610-5614, 1987.
31. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Davie EW, Roth GJ. The α and β chains of human platelet glycoprotein Ib are both transmembrane proteins containing leucine-rich amino acid sequences. Proc Natl Acad Sci USA 85:2135-2139, 1988.
32. Hickey MJ, Williams SA, Roth GJ. Human platelet glycoprotein IX. An adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. Proc Natl Acad Sci USA 86:6773-6777, 1989.
33. Shimomura T, Fujimura K, Maehama S et al. Rapid purification and characterization of human platelet glycoprotein V. The amino acid sequence contains leucine-rich repetitive modules as in glycoprotein Ib. Blood 75:2349-2356, 1990.
34. Roth GJ, Church TA, McMullen BA, Williams SA. Human platelet glycoprotein V: a surface leucine-rich glycoprotein related to adhesion. Biochem Biophys Res Commun 170:153-161, 1990.
35. Clemetson KJ. Biochemistry of platelet membrane glycoproteins. In: Jamieson GA, ed. Platelet Membrane Receptors: Molecular Biology, Immunology, Biochemistry, and Pathology. New York: Alan R Liss, 1988; 33-75.
36. Berndt MC, Gregory C, Kabral A, Zola H, Fournier D, Castaldi PA. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem 151:637-649, 1985.
37. Du X, Beutler L, Ruan C, Castaldi PA, Berndt MC. Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 69:1524-1527, 1987.
38. Modderman PW, Admiraal LG, Sonnenberg A, Von dem Borne AEG Kr. Glycoproteins V and Ib-IX form a non-covalent complex in the platelet membrane. J Biol Chem 267:364-369, 1992.
39. Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 261:12579-12585, 1986.
40. Vicente V, Kostel PJ, Ruggeri ZM. Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His1-Arg293 of the α-chain of glycoprotein Ib. J Biol Chem 263:18473-18479, 1988.
41. Vicente V, Houghton RA, Ruggeri ZM. Identification of a site in the a chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J Biol Chem 265:274-280, 1990.
42. Zucker MB, Kim SJ, McPherson J, Grant RA. Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol 35:535-549, 1977.
43. Moake JL, Olson JD, Troll JH, Tang SS, Funicella T, Peterson DM. Binding of radioiodinated human von Willebrand factor to Bernard-Soulier, thrombasthenic and von Willebrand's disease platelets. Thromb Res 19:21-27, 1980.
44. Caen JP, Nurden AT, Jeanneau C et al. Bernard-Soulier syndrome. A new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 87:586-596, 1976.
45. Weiss HJ, Tschopp TB, Baumgartner Hr, Sussman H, Johonson MM, Egan JJ. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium - further implications on the role of the von Willebrand factor in hemostasis. Am J Med 57:920-925, 1974.
46. Howard MA, Firkin BG. Ristocetin, a new tool in the investigation of platelet aggregation. Thromb Diath Haemmorrh 26:362-369, 1971.
47. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 85:318-328, 1975.
48. Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier syndrome platelets. J Clin Invest 61:861-864, 1978.
49. Wicki AN, Clemetson KJ. Structure and function of platelet membrane glycoproteins Ib and V. Effects of leukocyte elastase and other proteases on platelets response to von Willebrand factor and thrombin. Eur J Biochem 153:1-11, 1985.
50. Okumura T, Hasitz M, Jamieson JA. Platelet glycocalicin. Interaction with thrombin and role as thrombin receptor of the platelet surface. J Biol Chem 253:3435-3443, 1978.
51. Yamamoto K, Yamamoto N, Kitagawa H, Tanoue K, Kosaki G, Yamazaki H. Localization of a thrombin-binding site on human platelet membrane glycoprotein Ib determined by a monoclonal antibody. Thromb Haemostas 55:162-167, 1986.
52. Harmon JT, Jamieson GA. The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. J Biol Chem 261:13224-13229, 1986.
53. Katagiri Y, Hayashi Y, Yamamoto K, Tanoue K, Kosaki G, Yamazaki H. Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemostas 63:122-126, 1990.
54. Harmon JT, Jamieson GA. Platelet activation by thrombin in the absence of high affinity thrombin receptor. Biochemistry 27:2151-2157, 1988.
55. Jandrot-Perrus M, Rendu F, Caen JP, Levy-Toledano S, Guillin MJ. The common pathway for alpha- and gamma-thrombin-induced platelet activation is independent of GPIb: a study of Bernard-Soulier platelets. Br J Haematol 75:385-392, 1990.
56. Phillips DR, Agin PP. Platelet plasma membrane glycoproteins: identification of a proteolytic substrate from thrombin. Biochem Biophys Res Commun 75:940-947, 1977.
57. Mosher DF, Vaheri A, Choate JJ, Gahmberg CG. Action of thrombin on surface glycoproteins of human platelets. Blood 53:437-445, 1979.
58. Berndt MC, Phillips DR. Interaction of thrombin with platelets purification of the thrombin substrate. Ann NY Acad Sci 370:87-95, 1983.
59. Tam SW, Fenton JW, Detwiler TC. Platelet thrombin receptors: binding of alpha-thrombin is coupled to signal generation by chymotrypsin sensitive mechanism. J Biol Chem 255:6626-6632, 1980.
60. Watanabe K, Yamamoto M, Ando Y et al. Recognition of tryptic fragment by monoclonal antibody that inhibits thrombin and vWF interaction with platelets. Thromb Haemostas 54:60, 1985.
61. McGowan EB, Ding A, Detwiler TC. Correlation of thrombin-induced glycoprotein V hydrolysis and platelet activation. J Biol Chem 258:11243-11248, 1983.
62. Jandrot-Perrus M, Guillin M-C, Nurden AT. Human gamma-thrombin: lack of correlation between a platelet functional response and glycoprotein V hydrolysis. Thromb Haemostas 58:915-920, 1987.
63. Bienz D, Schnippering W, Clemetson KJ. Glycoprotein V is not the thrombin activation receptor on human blood platelets. Blood 68:720-725, 1986.
64. White GC, Knupp CL. Glycoprotein V hydrolysis by thrombin. Lack of correlation with secretion. Thromb Res 38:641-648, 1985.
65. Fox JEB. Identification of actin-binding protein as the protein linking the membrane skeleton to glycoproteins on platelet plasma membranes. J Biol Chem 260:11970-11977, 1985.
66. Fox JEB. Linkage of a membrane skeleton to integral membrane glycoprotein in human platelets. Identification of one of the glycoproteins as glycoproteins Ib. J Clin Invest 76:1673-1683, 1985.
67. Okita JR, Pidard D, Newman PJ, Montgomery RR, Kunicki TJ. On the association of glycoprotein Ib and actin-binding protein in human platelets. J Cell Biol 100:317-321, 1985.
68. White JG, Burris SM, Hasegawa D, Johnson M. Micropipette aspiration of human blood platelets: a defect in Bernard-Soulier's syndrome. Blood 63:1249-1252, 1984.
69. Wenger RH, Kieffer N, Wicki AN, Clemetson KJ. Structure of the human blood platelet membrane glycoprotein Iba gene. Biochem Biophys Res Commun 156:389-395, 1988.
70. Wenger RH, Wicki AN, Kieffer N, Adolph S, Hameister H, Clemetson KJ. The 5′ flanking region and chromosomal localization of the gene encoding human platelet membrane glycoprotein Ibα. Gene 85:517-524, 1989.
71. Hickey MJ, Deaven LL, Roth GJ. Human platelet glycoprotein IX. Characterization of cDNA and localization of the gene to chromosome 3. Fed Eur Biochem Sci 274:189-192, 1990.
72. Hickey MJ, Hagen FS, Yagi M, Roth GJ. Human platelet glycoprotein V. Characterization of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins. Proc Natl Acad Sci USA 90:8327-8331, 1993.
73. Lanza F, Morales M, de La Salle C et al. Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. J Biol Chem 268:20801-20807, 1993.
74. Ware J, Russel SR, Vincente V et al. Nonsense mutation in the glycoprotein Ib-α coding sequence associated with Bernard-Soulier syndrome. Proc Natl Acad Sci USA 87:2026-2030, 1990.
75. De Marco L, Mazzucato M, Fabris F et al. Variant Bernard-Soulier syndrome type Bolzano: a congenital bleeding disorder due to a structural and functional abnormality of the platelet glycoprotein Ib-IX complex. J Clin Invest 86:25-31, 1990.
76. Ware J, Russell SR, Marchese P et al. Point mutation in a leucine-rich repeat of platelet glycoprotein Ib resulting in the Bernard-Soulier syndrome. J Clin Invest 92:1213-1220, 1993.
77. Miller JL, Lyle VA, Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib-α leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood 79:439-446, 1992.
78. Aakhus AM, Stavem P, Hovig T, Pedersen TM, Solum NO. Studies on a patient with thrombocytopenia, giant platelets and a platelet membrane glycoprotein Ib with reduced amount of sialic acid. Br J Haematol 74:320-329, 1990.
79. Finch CN, Miller JL, Lyle VA, Handin RI. Evidence that an abnormality in the glycoprotein Ibα gene is not the cause of abnormal platelet function in a family with classic Bernard-Soulier disease. Blood 75:2357-2362, 1990.
80. Clemetson KJ, Wenger RH, Wicki AN, Kieffer N, Drouin J. Molecular biology of platelet membrange glycoprotein Ib (abstract). Thromb Haemostas 62 (Suppl 1):459a, 1989.
81. Drouin J, McGregor JL, Parmentier S, Izaguirre CA, Clemetson KJ. Residual amounts of glycoprotein Ib concomitant with near-absence of glycoprotein IX in platelets of Bernard-Soulier patients. Blood 72:1086-1088, 1988.
82. Wright SD, Michaelides K, Johnson DJD, West NC, Tuddenham EGD. Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 81:2339-2347, 1993.
83. Lopez JA, Leung B, Reynolds CC, Li CQ, Fox JEB. Efficient plasma membrane expression of a functional platelet glycoprotein Ib-IX complex requires the presence of its three subunits. J Biol Chem 267:12851-12859, 1992.
84. Takahashi H. Studies on the pathophysiology and treatment of von Willebrand disease. IV. Mechanism of the increased ristocetin-induced platelet aggregation in von Willebrand's disease. Thromb Res 19:857-867, 1980.
85. Weiss HJ, Meyer D, Rabionowitz R et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 306:326-333, 1982.
86. Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 60:790-794, 1982.
87. Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA 88:4761-4765, 1991.
88. Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib-α gene associated with a hyperactive surface receptor. Blood 81:1787-1791, 1993.
89. Takahashi H, Murata M, Furukawa T, Handa M, Watanabe K., Ikeda Y. A point mutation in gene encoding glycoprotein Ib-α in a Japanese family with platelet-type von Willebrand disease (abstract). Blood 80:130a, 1992.
90. Nieuwenhuis HK, Akkerman JWN, Houdijk WPM, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 318:470-472, 1985.
91. Kehrel B, Balleisen L, Kokott R et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 71:1074-1078, 1988.
92. Pischel KD, Bluestein HG, Woods VL Jr. Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. J Clin Invest 81:505-513, 1988.
93. Handa M, Nagai K, Kamata H et al. Defect of GPIa-IIa heterodimer complex in a patient whose platelets showed no response to collagen (abstract). Blood 72:323a, 1988.
94. Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemostas 64:74-79, 1990.
95. Santoro SA. Identification of a 160 000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 46:913-920, 1986.
96. Santoro SA, Rajpara SM, Staatz WD, Woods VLJ Jr. Isolation and characterization of a platelet surface collagen binding complex related to VLA-2. Biochem Biophys Res Commun 153:217-223, 1988.
97. 2+-dependent adhesion of platelets to collagen. J Cell Biol 108:1917-1924, 1989.
98. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84:1440-1445. 1989.
99. Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 69:1712-1720, 1987.
100. Kirchmaier CM, Meyer M, Schirmer A, Spangenberg P, Breddin HK. Thrombocytopathy Regensburg: a familial macrothrombocytopathy with abnormal platelet glycoprotein IIIb (IV) (abstract 1463). Thromb Haemostas 65:1102, 1991.
101. Tandon NN, Lipsky RH, Burgers WH, Jamieson GA. Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem 264:7570-7575, 1989.
102. a- platelets lack detectable GPIV (CD36). Blood 76:1698-1703, 1990.
103. Tandon NN, Ockenhouse CF, Greco NJ, Jamieson GA. Adhesive functions of platelets lacking GPIV (CD36). Blood 78:2809-2813, 1991.
104. Diaz-Ricart M, Tandon NN, Carretero M, Ordinas A, Bastida E, Jamieson GA. Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood 82:491-496, 1993.
105. Yamamoto N, Akamatsu N, Yamazaki H, Tanoue K. Normal aggregations of glycoprotein IV (CD36)-deficient platelets from seven healthy Japanese donors. Br J Haematol 81:86-92, 1992.
106. Agbanyo FR, Sixma JJ, DE Groot PG, Languino LR, Plow EF. Thrombospondin-platelet interactions. Role of divalent cations, wall shear rate, and platelet membrane glycoproteins. J Clin Invest 92:288-296, 1993.
107. Switalska HI, Niewiarowski S, Tuszynski GP, Rucinski B, Schimaier A, Morinelli TA. Radioimmunoassay of human platelet thrombospondin: different patterns of β-thromboglobulin antigen secretion and clearance from the circulation. J Lab Clin Med 106:690-700, 1985.
108. Leung LIK, Nachman RL. Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest 70:542-549, 1982.
109. Lahav J, Lawler J, Gimbrone MA. Thrombospondin interactions with fibronectin and fibrinogen: mutual inhibition in binding. Eur J Biochem 145:151-156, 1984.
110. Galvin NJ, Vance PM, Dixit VM, Frink B, Frazier WA. Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol 104:1413-1422, 1987.
111. Mumby SM, Raugi GJ, Bornstein P. Interaction of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J Cell Biol 98:646-652, 1984.
112. Tuszynski GP, Kowalska MA. Thrombospondin-induced adhesion of human platelets. J Clin Invest 87:1387-1394, 1991.
113. Beer JH, Rabaglio M, Berchtold P et al. Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction. Blood 82:820-829, 1993.
114. Nurden AT, Caen JP. An abnormal glycoprotein pattern in three cases in Glanzmann's thrombasthenia. Br J Haematol 28:253-260, 1974.
115. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 60:535-545, 1977.
116. Clemetson KJ, Capitanio A, Pareti FI, McGregor JL, Luscher EF. Additional platelet membrane glycoprotein abnormalities in Glanzmann's thrombasthenia: a comparison with normals by high resolution two-dimensional polyacrylamide gel electrophoresis. Thromb Res 18:797, 1980.
117. Caen JP, Castaldi PA, Leclerc JC et al. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia. Am J Med 41:4-26, 1966.
118. Lusher JM, Barnhart MI. Congenital disorders affecting platelets. Semin Thromb Hemost 4:123-186, 1977.
119. Hardisty RM, Dormandy KM, Hutton RA. Thrombasthenia: studies on three cases. Br J Haematol 10:371-387, 1964.
120. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75:1383-1395, 1990.
121. Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem 257:10458-10466, 1982.
122. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 258:10247-10252, 1983.
123. Kunicki TJ, Pidard D, Rosa J, Nurden AT. The formation of calcium-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood 58:268-278, 1981.
124. Fitzgerald LA, Phillips DR. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem 260:11366-11374, 1985.
125. 2+. Eur J Biochem 133:193-199, 1983.
126. Phillips DR, Charo IF, Parise LV, Fitzgerald A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843, 1988.
127. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 64:1393-1400, 1979.
128. Parise LV, Phillips DR. Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem 260:10698-10707, 1985.
129. Bennett JS, Vilaire G, Cines DB. Identification of the fibrinogen receptor on human platelets by photoaffinity labeling. J Biol Chem 257:8049-8054, 1982.
130. Bennett JS, Hoxie JA, Leitman SF, Vilaire G, Cines DB. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci USA 80:2417-2421, 1983.
131. Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem 262:992-1000, 1987.
132. Nachman RL, Leung LLK, Kloczewiak M, Hawiger J. Complex formation of platelet membrane glycoproteins IIb and IIIa with the formation D domain. J Biol Chem 259:8584, 1984.
133. White GC II, Workman EF Jr, Lundblad RL. Thrombin binding to thrombasthenic platelets. J Lab Clin Med 91:76-82, 1978.
134. 14C-ADP by thrombasthenic platelet membranes. Haemostasis 5:231-238, 1976.
135. Caen JP, Michel H. Platelet shape change and aggregation. Nature 240:148-149, 1972.
136. Gerrard JM. White JG. The influence of aspirin and indomethacin on the platelet contractile wave. Am J Pathol 82:513-521, 1976.
137. Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol 86:77-86, 1980.
138. Cohen I, Gerrard JM, White JG. Ultrastructure of clots during isometric contraction. J Cell Biol 93:775-787, 1982.
139. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843, 1988.
140. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 4:2868-2880, 1990.
141. Ruggeri ZM, Bader R, DeMarco L. Glanzmann's thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 79:6038-6041, 1982.
142. Berlinger S, Niiya K, Roberts JR, Hougten RA, Ruggeri ZM. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. J Biol Chem 263:7500-7505, 1988.
143. Gardner JM, Hynes RO. Interaction of fibronectin with its receptor on platelets. Cell 42:439-448, 1985.
144. Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 256:9477-9482, 1981.
145. Ginsberg MH, Forsyth HJ, Lightey A, Chediak J, Plow EF. Reduced surface expression and binding of fibronectin by thrombin-stimulated thrombasthenic platelets. J Clin Invest 71:619-625, 1983.
146. Parise LV, Phillips DR. Fibronectin-binding properties of the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem 261:14011-14017, 1986.
147. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231:1159-1162, 1986.
148. Thiagarajan P, Kelly KL. Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 263:3035-3038, 1988.
149. Mohri H, Hashimoto Y, Ohba M, Kumagai H, Ohkubo T. The novel effect of cyclicization of Arg-Gly-Asp-containing peptide on vitronectin binding to platelets. Am J Hematol 37:14-19, 1991.
150. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 254:5357-5363, 1979.
151. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with glycoprotein IIb-IIIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 77:1272-1277, 1986.
152. Asch E, Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85:1372-1378, 1990.
153. Ruggeri ZM, Bader R, De Marco L. Glanzmann's thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 79:6038-6041, 1982.
154. Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 72:1-12, 1983.
155. Hourdille P, Hasitz M, Belloc F, Nurden AT. Immunocytochemical study of the binding of fibrinogen and thrombospondin to ADP- and thrombin-stimulated human platelets. Blood 65:912-920, 1985.
156. Poncz MR, Eisman R, Heidenrech R et al. Structure of the platelet membrane glycoprotein IIb: homology to the a subunit of the vitronectin and fibronectin receptors. J Biol Chem 262:8476-8482, 1987.
157. Fitzgerald LA, Steiner B, Rail SC, Shan-shan L, Phillips DR. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to integrin. J Biol Chem 262:3936-3939, 1987.
158. Bray PF, Rosa JP, Johnston GI et al. Platelet glycoprotein IIb. Chromosomal localization and tissue expression. J Clin Invest 80:1812-1817, 1987.
159. Zimrin AB, Eisman R, Vilaire G, Schwartz E, Bennett JS, Poncz M. Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors. J Clin Invest 81:1470-1475, 1988.
160. Zimrin AB, Gidwitz S, Lord S et al. The genomic organization of platelet glycoprotein IIIa. J Biol Chem 265:8590-8595, 1990.
161. Rosa JP, Bray PF, Gayet O et al. Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17. Blood 72:593-600, 1988.
162. Prandini MH, Denarier E, Frachet P, Uzan G, Margnerie G. Isolation of the human platelet GPIIb gene and characterization of the 5′ flanking region. Biochem Biophys Res Commun 156:35-44, 1988.
163. Heidenreich R, Eisman R, Surry S et al. Organization of the gene for platelet glycoprotein IIb. Biochemistry 29:1232-1244, 1990.
164. Burk CD, Newman PJ, Lyman S, Gill J, Coller BS, Poncz M. A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia. J Clin Invest 87:270-276, 1991.
165. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA 88:3160-3164, 1991.
166. Kato A, Yamamoto K, Miyazaki S, Jung SM, Moroi M, Aoki N. Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex. Blood 79:3212-3218, 1992.
167. Gu JM, Xu WF, Wang XD, Wu QY, Chi CW, Ruan CG. Identification of a nonsense mutation at amino acid 584-arginine of platelet glycoprotein IIb in patients with type I Glanzmann thrombasthenia. Br J Haematol 83:442-449, 1993.
168. [168) Bray PF, Shuman MA. Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann's thrombasthenia. Blood 75:881-888, 1990.
169. Simsek S, Heyboer H, De Bruijne-Admiraal LG, Goldschmeding R, Cuijpers HThM, Von dem Borne AEG Kr. Glanzmann's thrombasthenia caused by homozygosity for a splice defect that leads to deletion of the first coding exon of the glycoprotein IIIa mRNA. Blood 81:2044-2049, 1993.
170. 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 249:915-918, 1990.
171. 214Trp mutation. J Clin Invest 89:1995-2004, 1992.
172. 3 (platelet glycoprotein IIb/IIIa) helps define a ligand binding site. J Biol Chem 267:3789-3794, 1992.
173. Agranoff BW, Murthy P, Seguin EB. Thrombin-induced phosphodiesteratic cleavage of phosphatidylinositol bisphosphate in human platelets. J Biol Chem 258:2076-2078, 1983.
174. 3H]inositol triphosphate formation in indomethacin-treated human platelets. Biochem J 226:831-837, 1985.
175. 2+ mobilization during stimulation. Proc Natl Acad Sci USA 80:965-968, 1983.
176. Siess W, Boehlig B, Weber PC, Lapetina EG. Prostaglandin endoperoxides analogs stimulate phospholipase C and protein phosphorylation during platelet shape change. Blood 65:1141-1148, 1985.
177. Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin secretion, and aggregation. J Biol Chem 258:11236-11242, 1983.
178. Cockcroft S, Gomperts BD. Role of guanine nucleotide binding protein in the activation of polyphosphoinositide phosphodiesterase. Nature 314:534-536, 1985.
179. Houslay MD, Bojanic D, Wilson A. Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. Biochem J 234:737-740, 1986.
180. Grandt R, Aktories K, Jakobs KH. Evidence for two GTPases activated by thrombin in membranes of human platelets. Biochem J 237:669-674, 1986.
181. Houslay MD, Bojanic D, Wilson A, Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. Biochem J 234:737-740, 1986.
182. Brass LF, Shaller CC, Belmonte EJ. Inositol 1,4,5-triphosphate-induced granule secretion in platelets: evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 79:1269-1275, 1987.
183. 2 receptor in human platelets is a member of novel Gq family. J Biol Chem 266:9309-9313, 1991.
184. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 308:693-698, 1984.
185. Berridge MJ. Inositol triphosphate and diacylglycerol as second messengers. Biochem J 220:345-360, 1984.
186. Berridge MJ, Irvine RE. Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 312:315-321, 1984.
187. Kishimoto A, Takai Y, Mori T, Kikkawa U, Nishizuka Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol: its possible relation to phosphatidylinositol turnover. J Biol Chem 255:2273-2276, 1980.
188. 2+-transporting membrane vesicle fraction from human platelets. J Biol Chem 260:956-962, 1985.
189. 2+ release from human platelet membranes. Biochem Biophys Res Commun 128:1274-1280, 1985.
190. Lyons RM, Stanford N, Majerus PW. Thrombin-induced protein phosphorylation in human platelets. J Clin Invest 56:924-936, 1975.
191. Daniel JL, Holmsen H, Adelstein RS. Thrombin-stimulated myosin phosphorylation in intact platelets and its possible involvement secretion. Thromb Haemostas 38:984-989, 1977.
192. Fuse I, Tai HH. Stimulations of arachidonate release and inositol-1,4,5-triphosphate formation are mediated by distinct G-proteins in human platelets. Biochem Biophys Res Commun 146:659-665, 1987.
193. 2 activation. Biochem Biophys Res Commun 148:971-978, 1987.
194. Hallam TJ, Rink TJ. Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator quin 2. J Physiol 368:131-146, 1985.
195. Hallam TJ, Rink TJ. Agonists stimulate divalent cation channels in the plasma membrane of human platelets. FEBS Lett 186:175-179, 1985.
196. Doyle VM, Ruegg UT. Lack of evidence for voltage dependent calcium channels on platelets. Biochem Biophys Res Commun 127:161-167, 1985.
197. Avdonin PV, Cheglakov IB, Boogry EM, Svitina-Ulitina IV, Mazaev AV, Tkachuk VA. Evidence for the receptor-operated calcium channels in human platelet plasma membrane. Thromb Res 46:29-37, 1987.
198. Sage SO, Rink TJ. The kinetics of changes in intracellular calcium concentration in fura-2-loaded human platelets. J Biol Chem 262:16364-16369, 1987.
199. Mahaut-Smith MP, Sage SO, Rink TJ. Receptor-activated single channels in intact human platelets. J Biol Chem 265:10479-10483, 1990.
200. 2+. Biochem J 240:917-920, 1986.
201. 2+ influx in platelets. Biochim Biophys Acta 940:141-148, 1988.
202. 2+ transport across the platelet plasma membrane: a role for membrane glycoproteins IIb and IIIa. J Biol Chem 260:2231-2236, 1985.
203. 2+ influx into stimulated platelets. Blood 66:731-734, 1985.
204. Fujimoto T, Fujimura K, Kuramoto A. Electrophysiological evidence that glycoprotein IIb-IIIa complex is involved in calcium channel activation on platelet plasma membrane. J Biol Chem 266:16370-16375, 1991.
205. Holmsen H, Weiss HJ. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathis: 'storage pool disease'. Blood 39:197-209, 1972.
206. White JG, Gerrard JM. Ultrastrucural features of abnormal blood platelets. Am J Pathol 83:590-614, 1976.
207. Nieuwenhuis HK, Akkerman JWN, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred and six patients. Blood 70:620-623, 1987.
208. Israels SJ, McNicol A, Robertson C, Gerrard JM. Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation. Br J Haematol 75:118-121, 1990.
209. Holmsen H, Weiss HJ. Secretable storage pools in platelets. Annu Rev Med 30:119-134, 1979.
210. Akkerman JWN, Nieuwenhuis HK, Mommersteeg-Leautaud ME, Gorter G, Sixma JJ. ATP-ADP compartmentation in storage pool deficient platelets: correlation between granule-bound ADP and the bleeding time. Br J Haematol 55:135-143, 1983.
211. Holmsen H, Weiss HJ. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 19:643-649, 1970.
212. Lages BA, Holmsen H, Weiss HJ, Dangelmaier C. Thrombin and ionophore A23187-induced dense granule secretion in storage pool deficient platelets: evidence for impaired nucleotide storage as the primary dense granule defect. Blood 61:154-162, 1983.
213. Malmsten C, Kindahl H, Samuelsson B, Levy-Toledano S, Tobelem G, Caen JP. Thromboxane synthesis and the platelet release reaction in Bernard-Soulier syndrome, thrombasthenia Glanzmann and Hermansky-Pudlak syndrome. Br J Haematol 35:511-520, 1977.
214. 2, collagen, and epinephrine in 12 patients with storage pool deficiency. Blood 57:27-31, 1981.
215. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood 14:162-169, 1959.
216. Rendu F, Breton-Gorius J, Lebert M et al. Evidence that abnormal platelet functions in human Chediak-Higashi syndrome are the result of lack of dense bodies. Am J Pathol 111:307-314, 1983.
217. Grottum KA, Hovig T, Holmsen H, Abrahamsen AF, Jeremic M, Seip M. Wiskott-Aldrich syndrome: qualitative defects and short platelet survival. Br J Haematol 17:373-388, 1969.
218. Day HJ, Holmsen H. Platelet adenine nucleotide 'storage pool deficiency' in thrombocytopenic absent radii syndrome. J Am Med Assoc 221:1053-1054, 1972.
219. Levy-Toledano S, Caen JP, Breton-Gorius J et al. Gray platelet syndrome: a granule deficiency. Its influence on platelet function. J Lab Clin Med 98:831-848, 1981.
220. Rosa JP, George JN, Bainton DF et al. Gray platelet syndrome: demonstration of a granule membranes that can fuse with the cell surface. J Clin Invest 80:1138-1146, 1987.
221. Breton-Gorius J, Vainchenker W, Nurden AT, Levy-Toledano S, Caen JP. Defective a granule production in megakaryocytes from gray platelet syndrome. Ultrastrucural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 102:10-19, 1981.
222. Nurden AT, Kunicki TTJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies on platelets isolated from two patients with the gray platelet syndrome. Blood 59:709-718, 1982.
223. Caen JP, Deschamps JF, Bodevin E, Bryckaert MC, Dupuy E, Wasteson A. Megakaryocytes and myelofibrosis in gray platelet syndrome. Nouv Rev Fr d'Hematol 29:109-114, 1987.
224. 2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin injestion. Br J Haematol 32:257-272, 1976.
225. Rendu F, Breton-Gorius J, Trugnan G et al. Studies on a new variant of the Hermansky-Pudlak syndrome: qualitative, ultrastructural, and functional abnormalities of the platelet-dense bodies associated with a phospholipase A defect. Am J Hematol 4:387-399, 1978.
226. Okuma M. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders. Acta Haematol Jpn 43:1139-1144, 1980.
227. Jubelirer SJ, Russel F, Vaillancourt R, Deykin D. Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood 56:728-731, 1980.
228. Rao AK, Koike K, Willis J et al. Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. Blood 64:914-921, 1984.
229. Hamberg M, Svensson J, Samuelsson B. Thromboxanes. A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998, 1975.
230. Malmsten C, Hamberg M, Svensson J, Samuelsson B. Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency. Proc Natl Acad Sci USA 72:1446-1450, 1975.
231. DeChavanne M, LaGarde M. Thrombocytopathies avec deficit en cyclo-oxygenase. Nouv Rev Fr d'Hematol 16:421-426, 1976.
232. LaGarde M, Byron PA, Vargaftig BB, DeChavanne M. Impairment of platelet thromboxane A2 generation and of the platelet release reaction in two patients with congenital deficiency of platelet cyclo-oxygenase. Br J Haematol 38:251-266, 1978.
233. Nyman D, Eriksson AW, Lehmann W, Blomback M. Inherited defective platelet aggregation with arachidonate as the main expression of a defective metabolism of arachidonic acid. Thromb Res 14:739-746, 1979.
234. Rak K, Boda Z. Haemostatic balance in congenital deficiency of platelet cyclo-oxygenae. Lancet 2:44, 1980.
235. Boda Z, Tamas E, Altorjay I, Pfliegler G, Rak K. Congenital deficiency of cyclo-oxygenase in a woman with generalized atherosclerosis. Scand J Haematol 27:65-69, 1981.
236. Rao GHR, White JG. Epinephrine potentiation of arachidonate-induced aggregation of cyclo-oxygenase deficient platelets. Am J Hematol 11:355-366, 1981.
237. Pareti FI, Mannucci PM, D'Angelo A, Smith JB, Sautebin L, Galli G. Congenital deficiency of thromboxane and prostacyclin. Lancet 1:898-900, 1980.
238. Horellou MH, Lecompte T, Lecrubier F et al. Familial and constitutional bleeding disorder due to platelet cyclo-oxygenase deficiency. Am J Hematol 14:1-9, 1983.
239. Nakanishi K, Ikeda K, Hato T et al. Platelet cyclo-oxygenase deficiency in a Japanese. Scand J Haematol 32:167-174, 1984.
240. Christ EJ, Van Dorp DA. Comparative aspects of prostaglandin biosynthesis in animal tissues. Biochim Biophys Acta 270:537-545, 1972.
241. Weiss HJ, Lages BA. Possible congenital defect in platelet thromboxane synthase. Lancet 2:760-761, 1977.
242. Mestel F, Oetliker O, Beck E, Felix R, Imbach P, Wagner HP. Severe bleeding associated with defective thromboxane synthase. Lancet 1:157, 1980.
243. 2 synthetase deficiency: reorientation of cyclic endoperoxide metabolism. Br J Haematol 49:29-41, 1981.
244. Vermylen J, Carreras LO, van Schaeren J, Defreyn G, Machin SJ, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1:1073-1075, 1981.
245. 2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Thromb Res 11:323-344, 1977.
246. Moncada S, Vane JR. The discovery of prostacyclin (PGX): a fresh insight into arachidonic acid metabolism. In: Kharash N, Fried J, eds. Biochemical Aspects of Prostaglandins and Thromboxanes. New York: Academic Press, 1977; 155-177.
247. Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2. J Clin Invest 67:1801-1804, 1981.
248. Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 57:545-552, 1981.
249. 2. Br J Haematol 48:293-303, 1981.
250. 2 in a patient with chronic myeloid leukemia. Br J Haematol 51:469-477, 1982.
251. 2 receptor from human blood platelets. J Biol Chem 264:16496-16501, 1989.
252. 2 receptor. Nature 349:617-620, 1991.
253. Brass LF, Shaller CC, Belmonte EJ. Inositol 1,4,5-triphosphate-induced granule secretion in platelets: evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 79:1269-1275, 1987.
254. Nakano T, Hanasaki K, Arita H. Role of protein kinase C in U46619-induced platelet shape change, aggregation and secretion. Thromb Res 56:299-306, 1989.
255. Pollock WK, Armstrong RA, Brydon LJ, Jones RL, MacIntyre DE. Thromboxane-induced phosphatide formation in human platelets. Biochem J 219:833-842, 1984.
256. Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. J Biol Chem 258:11236-11242, 1983.
257. 2), a stable analogue of thromboxane A2, in human platelets. Thromb Res 41:811-818, 1986.
258. 2 analogue. Thromb Res 41:761-770, 1986.
259. 2 analogue in human platelets. Biochem Biophys Res Commun 117:663-669, 1983.
260. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 266:9309-9313, 1991.
261. 2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemostas 57:158-164, 1987.
262. 2 activation. Blood 81:994-1000, 1993.
263. 2 receptor in a patient with polycythemia vera. Thromb Haemostas 67:144-146, 1992.
264. 2+ transport defect?). Acta Haematol Jpn 44:969-972, 1981.
265. Machin SJ, Keenan JP, McVerry BA. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. J Clin Pathol 36:1140-1144, 1983.
266. Hardisty RM, Machin SJ, Nokes TJC, Rink TJ, Smith SW. A new congenital defect of platelet secretion: impaired responsiveness of the platelets to cytoplasmic free calcium. Br J Haematol 53:543-557, 1983.
267. Feinman RD, Detwiler JC. Platelet secretion induced by divalent cationophores. Nature 249:172, 1974.
268. 2+ mobilization in patients with congenital cyclo-oxygenase deficiency and with defective platelet aggregation to A23187. Acta Haematol Jpn 52:1522-1533, 1989.
269. Rao K., Kowalska A, Disa J. Impaired cytoplasmic ionized calcium mobilization in inherited platelet secretion defects. Blood 74:664-672, 1989.
270. Degos L, Tobelem G, Lethielleux P, Levy-Toledano S, Caen J, Colombani J. Molecular defects in platelets from patients with Bernard-Soulier syndrome. Blood 50:899-903, 1977.
271. Drouin J, McGregor JL, Clemetson KJ, Hashemi S. An alloantibody to platelet glycoprotein V in a patient with Bernard-Soulier syndrome inhibits ristocetin-induced platelet aggregation (abstract). Blood 74:31a, 1989.
272. Cuthbert RJG, Watson HHK, Handa SI, Abbott I, Ludlam CA. DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 49:649-650, 1988.
273. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Haematol 33:39-45, 1990.
274. Kobrinsky NL, Israels ED, Gerrard JM et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1:1145-1148, 1984.
275. Mannucci DM, Vicente V, Vianello L et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 67:1148-1153, 1986.
276. Nieuwenhuis HK, Sixma JJ. 1-deamino-8-D-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency. Ann Intern Med 108:65-67, 1988.
277. Schulman S, Johnsson H, Egberg N, Blomback M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 45:165-174, 1987.
278. Ruggeri ZM, Ponticelli C, Mannucci PM. Factor VIII and chronic renal failure. Br Med J i:1085, 1977.
279. Bern MM, Klumpar DI, Wheeler WE, Davis GL. Factor VIII complex in CRF: influence of protein C, fibrinolysis and diabetes mellitus. Thromb Res 31:177-186, 1983.
280. Lewis JH, Zucker MB, Ferguson JH. Bleeding tendency in uremia. Blood 11:1073-1076, 1956.
281. Stiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Haematol 7:107-117, 1979.
282. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 68:337-342, 1986.
283. Zwaginga JJ, Ijsseldijk MJW, Beesser-Visser N, de Groot PG, Vos J, Sixma JJ. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75:1498-1508, 1990.
284. Winter M, Seghatchian MJ, Cameron JS. An abnormal factor VIII molecule in uremia? Lancet 1:1112, 1983.
285. Gralnick HR, McKeown LP, Williams SB, Shaffer BC. Plasma and platelet von Willebrand's factor defects in uremia. Am J Med 85:806-810, 1988.
286. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8-12, 1983.
287. Escolar G, Cases A, Bastida E et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76:1336-1340, 1990.
288. Komarnicki M, Twardowski T. Platelet glycoprotein concentrations in patients with chronic uremia. Folia Haematol (Leipz) 114:642-645, 1987.
289. Castaldi PA, Rozemberg MC, Stewart JH. The bleeding disorder of uraemia: a qualitative platelet defect. Lancet ii:66-69, 1966.
290. Evans EP, Branch RA, Bloom AL. A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 25:745-753, 1972.
291. Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uraemia: multifaceted defect partially corrected by dialysis. Am J Med 79:552-559, 1985.
292. DiMinno G, Cerbone A, Usberti M et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108:246-252, 1986.
293. Turney JH, Woods HF, Fewell MR, Weston MJ. Factor VIII complex in uraemia and effects of haemodialysis. Br Med J 282:1653-1656, 1981.
294. Rao AK. Uraemic platelets. Lancet i:913-914, 1986.
295. Remuzzi G, Benigni A, Dodesini P et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 71:762-768, 1983.
296. Vlachoyannis J, Schoeppe W. Adenylate cyclase activity and cyclic AMP content of human platelets in uraemia. Eur J Clin Invest 12:379-381, 1982.
297. Gura V, Creter D, Levi J. Elevated thrombocyte calcium content in uraemia and its correction by 1 (OH) vitamin D treatment. Nephron 30:237-239, 1982.
298. Moosa A, Greaves M, Brown CB, MacNeil S. Elevated platelet-free calcium in uraemia. Br J Haematol 74:300-305, 1990.
299. 2+ in platelets from patients with uraemia. Blood 73:172-176, 1989.
300. Horowitz HI, Cohen BD, Martinez P, Papayoanou MF. Defective ADP-induced platelet factor 3 activation in uremia. Blood 30:331-340, 1967.
301. Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 49:336-345, 1970.
302. Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 49:346-351, 1970.
303. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 86:1768-1771, 1990.
304. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148:1482-1489, 1987.
305. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87:5193-5197, 1990.
306. Remuzzi G, Marchesi D, Livio M et al. Altered platelet and vascular prostaglandin generation in patients with renal failure and prolonged bleeding times. Thromb Res 13:1007-1015, 1978.
307. Remuzzi G, Livio M, Cavenaghi AE et al. Unbalanced prostaglandin syntheis and plasma factors in uraemic bleeding. A hypothesis. Thromb Res 13:531-536, 1978.
308. Livio M, Marchesi D, Remuzzi G, Gotti E, Mecca G, De Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet ii:1013-1015, 1982.
309. Moia M, Mannucci PM, Vizzoto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2:1227-1229, 1987.
310. Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 59:139-148, 1985.
311. Escolar G, Cases A, Monteagudo J et al. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 114:36-42, 1989.
312. Vigano GL, Mannucci PM, Lattuada A, Harris A, Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 31:32-35, 1989.
313. Janson PA, Jubelirer JJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318-1322, 1980.
314. Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet ii:887-889, 1984.
315. Livio M, Mannucci PM, Vigano GL et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 315:731-735, 1986.
316. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet NHDM. Transient neurologic and occular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
317. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated to a-adrenergic receptors. N Engl J Med 299:505-509, 1978.
318. Eche N, Sie P, Caranobe C, Nouvel C, Pris J, Boneu B. Platelets in myeloproliferative disorders. III. Glycoproteins profile in relation to platelet function and platelet density. Scand J Haematol 26:123-129, 1981.
319. Mazzucato M, Marco LD, Angelis VD, Roai DD, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 73:369-374, 1989.
320. 2 in patients with myeloproliferative disorders. Blood 52:618-626, 1978.
321. 2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest 64:586-590, 1979.
322. Moore A, Nachman RL. Platelet Fc receptor. Increased expression in myeloproliferative disease. J Clin Invest 67:1064-1071, 1981.
323. Semararo N, Cortelazzo S, Colucci M, Barbui T. A hitherto undescribed effect of platelet coagulant activity in polycythemia vera and essential thrombocythemia. Thromb Res 16:795-802, 1979.
324. Crook M, Machin SJ, Crawford N. Basal induced prothrombinase expression in platelets from patients with essential thrombocythemia (ET). Br J Haematol 76:256-259, 1990.
325. Castaldi PA, Berndt MC, Booth W, Gregory C, Bull H, Greaves M. Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res 27:601-609, 1982.
326. Caranobe C, Sie P, Nouvel C, Laurent G, Pris J, Boneu B. Platelets in myeloproliferative disorders. II. Serotonin uptake and storage. Correlations with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 25:289-295, 1980.
327. Pareti FI, Gugliotta L, Mannuci L, Guarini A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemostas 47:84-89, 1982.
328. Russell NH, Salmon J, Keenan JP, Bellingham AJ. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 22:389-397, 1981.
329. Boughton BJ, Allington MJ, King A. Platelet plasma thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 40:125-132, 1978.
330. Keenan JP, Wharton J, Shephard AJN, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. Br J Haematol 35:275-283, 1977.
331. Okuma M. Platelet function and its disorders - some aspects from the arachidonic acid metabolism. Acta Haematol Jpn 47:1542-1555, 1984.
332. Okuma M, Uchino H, Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 54:1258-1271, 1979.
333. Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 306:381-386, 1982.
334. Fujimoto T, Fujimura K, Kuramoto A. Measurement of platelet ionized calcium in patients with myeloproliferative disorders by Aequorin method. Thromb Haemostas 58:479, 1987.
335. Baker RI, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities and change with time. Eur J Haematol 40:267-272, 1988.
336. Fujimoto T, Fujimura K, Kuramoto A. Low intracellular calcium concentration in platelets after stimulation in patients with myeloproliferative disorders. Acta Haematol Jpn 52:118-125, 1989.
337. 2+ accumulation into the dense tubular system. Thromb Res 53:99-108, 1989.
338. Ushikubi F, Okuma M, Ishibashi T, Narumiya S, Uchino H. Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. Am J Hematol 33:96-100, 1990.
339. Cortelazzo S, Gali M, Castagna D, Viero P, de Gaetano G, Barbui T. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders. Thromb Haemostas 59:73-76, 1988.
340. 2 dehydrogenase in patients with myeloproliferative disorders. Prostaglandins Leukotrienes Med 21:207-220, 1986.
341. Fabris G, Casonato A, Del Ben MG, De Marco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 63:75-83, 1986.
342. DiMinno G, Coraggio F, Cerbone AM et al. A myeloma protein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 77:157-164, 1986.
343. Mohri H, Noguchi T, Kodama F, Itoh A, Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 87:663-668, 1987.
344. Bovill EG, Ershler WB, Golden EA, Tindle BH, Edson JR. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 85:115-123, 1986.
345. Clancy R, Jenkins E, Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopenic purpura. N Engl J Med 286:622-626, 1972.
346. Heyns AP, Fraser J, Retief FP. Platelet aggregation in chronic idiopathic thrombocytopenic purpura. J Clin Pathol 31:1239-1243, 1978.
347. Karpatkin S, Lackner HL. Association of antiplatelet antibody with functional platelet disorders: autoimmune thrombocytopenic purpura, systemic lupus erythematosus and thrombopathia. Am J Med 59:599-604, 1975.
348. Zahavi J, Marder VJ. Acquired 'storage pool disease' of platelets associated with circulating antiplatelet antibodies. Am J Med 56:883-890, 1974.
349. Weiss HJ, Rosove MH, Lages BA, Kaplan KL. Acquired storage pool deficiency with increased platelet-associated IgG. Report of five cases. Am J Med 69:711-717, 1980.
350. Fuse I, Hattori A, Higashihara M et al. A defect of platelet release reaction in a patient with SLE: impaired platelet aggregation induced by phorbol ester with a normal phosphorylation of 40K. protein. Scand J Haematol 36:44-54, 1986.
351. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systmeic lupus erythematosus. Blood 31:806-812, 1968.
352. Poole-Wilson PA, Jones NF. Acquired von Willebrand's syndrome and systemic lupus erythematosus. Proc R Soc Med 65:561-562, 1972.
353. Woods VL, Kurata Y, Montgomery RR et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 64:156-160, 1984.
354. Szatkowski NS, Kunicki TJ, Aster RH. Identification of glycoprotein Ib as a target for autoantibody in idiopathic (autoimmune) thrombocytopenic purpura. Blood 67:310-315, 1986.
355. Woods VL, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 63:368-375, 1984.
356. Tomiyama Y, Kurata Y, Mizutani H et al. Platelet glycoprotein IIb as a target antigen in two patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 66:535-538, 1987.
357. Beardsley DS, Spiegel JE, Jacobs MM, Handin RI, Lux IV SE. Platelet membrane glycoprotein IIIa contains target antigens that bind anti-platelet antibodies in immune thrombocytopenias. J Clin Invest 74:1701-1707, 1984.
358. Stuart MJ, Kelton JG, Allen JB. Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. Blood 58:326-359, 1981.
359. Hillbom M, Muuronen A, Neiman J. Liver disease and platelet function in alcoholics. Br Med J 295:581, 1987.
360. Laffi G, Leone G, Federi M et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenter 90:274-282, 1986.
361. Solum NO, Rigollot C, Budzynski AZ, Marder VJ. A quantitative evaluation of the inhibition of platelet aggregation by low-molecular-weight degradation products of fibrinogen. Br J Haematol 24:419-434, 1973.
362. Raman BKS, Van Slyck EJ, Riddle J, Sawdyk MA, Abraham JP, Saeed SM. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome and secondary thrombocytosis. Am J Clin Pathol 91:647-655, 1989.
363. Cowan DH, Graham RC Jr, Baunach D. The platelet defect in leukemia. J Clin Invest 59:188-200, 1975.
364. Cowan DH, Haut MJ. Platelet function in acute leukemia. J Lab Clin Med 79:893-905, 1972.
365. Chen Y, Wu QY, Wang Z et al. Abnormalities of platelet membrane glycoproteins in acute non-lymphoblastic leukemia (abstract). Thromb Haemostas 62:176, 1989.
366. Bray PF, Barsh G, Rosa JP, Luo XY, Magenis E, Shuman MA. Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIa. Proc Natl Acad Sci USA 85:8683-8687, 1988.
367. Yufu Y, Hashimoto M, Muta K, Ideguchi H, Nishimura J, Nawata H. Abnormality of platelet membrane glycoprotein GPIIb in a myelodysplastic syndrome with 3q inversion presenting with marked dysmegakaryopoiesis. Acta Haematol 83:107-110, 1990.
368. Berndt MC, Kabral A, Grimsley P, Watson N, Robertson TI, Bradstock KF. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 68:97-101, 1988.
369. Bick RL. Platelet function defects: a clinical review. Sem Thromb Hemostas 18:167-185, 1992.
370. Roth GJ, Stanford NS, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sei USA 72:3073-3076, 1975.
371. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61:314-319, 1978.
372. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet therapy. Br Med J 296:320-331, 1988.
373. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994.
374. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 83:885-898, 1994.
375. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294, 1994.